ANI Pharma 2025 rev ~$854-873M, Cortrophin Gel up 76% YoY; 2026 rev target $1.06-1.12B

ANI PHARMACEUTICALS INC

2025-FY EPS reported $3.32 vs consensus $2.04 ▲ beat (+63.1%)

Full-year 2025 total net revenues expected within or above $854M-$873M guidance ( ~39% YoY growth).
Cortrophin Gel net rev $347.8M in 2025 (+76% YoY); Q4 Cortrophin Gel $111.4M (+88% YoY).
2026 guidance: total net rev $1,055M-$1,115M, Cortrophin Gel $540M-$575M, adj EBITDA $275M-$290M, adj EPS $8.83-$9.34.
Plans to expand Rare Disease sales force by ~90 in mid-2026 to target acute gouty arthritis flares.
Unrestricted cash $285M at Dec 31, 2025; ILUVIEN+YUTIQ combined rev $74.9M in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.